Analysis Of Income And Expense [Abstract]

Xbrane Biopharma - Filing #679208

Concept 2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue
238 729 SEK
57 618 SEK
Material income and expense [abstract]
Research and development expense
305 783 SEK
199 648 SEK
Finance income (cost)
137,000 SEK
2 296 SEK
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income
0 SEK
0 SEK
388 373 SEK
388 172 SEK
201,000 SEK
SEK
167 356 SEK
172 513 SEK
5 157 SEK
SEK
Comprehensive income attributable to non-controlling interests, continuing and discontinued operations [abstract]
Comprehensive income, attributable to non-controlling interests
SEK
SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.